Product logins

Find logins to all Clarivate products below.


Clarivate Epidemiology’s coverage of dyslipidemia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the total and diagnosed prevalence of dyslipidemia for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe and 10 years for the other countries we cover.

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology’s dyslipidemia forecast answers the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of dyslipidemia?
  • In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of dyslipidemia?
  • How will improvements in survival change the number of people living with a diagnosis of dyslipidemia?
  • Of all people diagnosed with dyslipidemia, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of dyslipidemia over the forecast period?

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following dyslipidemia subpopulations:

  • Total dyslipidemia prevalent cases.
  • Total dyslipidemia prevalent cases by disease subtype.
  • Primary prevention prevalent cases by disease subtype.
  • Secondary prevention prevalent cases by disease subtype.
  • Total dyslipidemia prevalent cases by diagnosis scheme.
  • Diagnosed prevalent cases by treatment scheme.

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Gene Therapy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Approximately 80% of rare diseases have a genetic etiology. Gene therapies have the potential to transform the treatment of rare diseases and, in some cases, provide a functional cure. The pipeline…
Report
Gout – Current Treatment – Treatment Algorithms: Claims Data Analysis – Gout (US)
Gout, a form of inflammatory arthritis, arises due to the persistent elevation of serum uric acid (sUA) levels. The condition manifests through sudden and intense gout flares, causing significant…
Report
Dry Eye – Landscape & Forecast – Disease Landscape & Forecast (G7)
Dry eye disease (DED) is characterized by the loss of tear film homeostasis, caused by the inadequate production or the rapid evaporation of tears. The DED market is evolving rapidly, driven by…
Report
Epilepsy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Epilepsy is a complex neurological disorder marked by recurrent seizures, affecting approximately 4.7 million people across the major markets, as reported by Clarivate Epidemiology. Given epilepsy…
Report
Asthma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The asthma therapy market consists of many well-established drugs, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s Spiriva…